Sequenciamento do Proto-oncogene RET em uma Coorte de Pacientes com Carcinoma Medular de Tireoide do Estado da Bahia, Brasil
DOI:
https://doi.org/10.32635/2176-9745.RBC.2024v70n4.4738Palavras-chave:
Carcinoma Medular, Neoplasias da Glândula Tireoide, Mutação, Neoplasia Endócrina Múltipla Tipo 2a, Polimorfismo GenéticoResumo
Introdução: O carcinoma medular da tireoide é um câncer raro que se origina nas células C parafoliculares e pode ser esporádico ou hereditário. Tanto as doenças esporádicas quanto as hereditárias são causadas principalmente por mutações no proto-oncogene RET.Objetivo: Investigar
variantes germinativas patogênicas do gene RET em uma coorte de pacientes com carcinoma medular da tireoide no Estado da Bahia. Método: Estudo transversal, descritivo, envolvendo pacientes com diagnóstico histopatológico de carcinoma medular da tireoide, encaminhados para testes moleculares de 2020 a 2022. Dados clínicos e patológicos foram coletados de dados médicos. O DNA genômico foi extraído do sangue periférico. Os éxons 10, 11, 13, 14 e 15 do RET foram amplificados usando a técnica de reação em cadeia da polimerase e posteriormente sequenciados usando o método de Sanger. Resultados: O estudo incluiu 29 pacientes (82,8% mulheres). A idade média no diagnóstico foi de 46,5 ± 13,1 anos, e o tamanho médio do tumor foi de 2,1 ± 1,4 cm. De acordo com a classificação
TNM, 38% dos tumores foram estadiados como T1a, 27,6% como T1b, 24,1% como T2 e 10,3% como T3. Metástase linfonodal regional (N1) esteve presente em 44,8% dos casos. Metástase a distância (M1) para o mediastino foi observada em um caso (3,4%). Variantes do RET foram identificadas em 55,2% dos pacientes. A variante patogênica C634R foi identificada em um paciente (3,4%). Conclusão: Este estudo conseguiu descrever o perfil clínico e molecular de pacientes com carcinoma medular de tireoide no Estado da Bahia.
Downloads
Referências
Viola D, Elisei R. Management of medullary thyroid cancer. Endocrinol Metab Clin North Am. 2019;48(1):285-301. doi: https://doi.org/10.1016/j.ecl.2018.11.006 DOI: https://doi.org/10.1016/j.ecl.2018.11.006
Maia AL, Wajner SM, Vargas CV. Advances and controversies in the management of medullary thyroid carcinoma. Curr Opin Oncol. 2017;29(1):25-32. doi: https://doi.org/10.1097/CCO.0000000000000340 DOI: https://doi.org/10.1097/CCO.0000000000000340
Ceolin L, Duval MADS, Benini AF, et al. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. Endocr Relat Cancer. 2019;26(9):R499-518. doi: https://doi.org/10.1530/ERC-18-0574 DOI: https://doi.org/10.1530/ERC-18-0574
Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985;42(2):581-88. doi: https://doi.org/10.1016/0092-8674(85)90115-1 DOI: https://doi.org/10.1016/0092-8674(85)90115-1
Kawai K, Takahashi M. Intracellular RET signaling pathways activated by GDNF. Cell Tissue Res. 2020;382(1):113-23. doi: https://doi.org/10.1007/s00441-020-03262-1 DOI: https://doi.org/10.1007/s00441-020-03262-1
Takahashi M. Structure and expression of the ret transforming gene. IARC Sci Publ. 1988;(92):189-97.
Avantaggiato V, Dathan NA, Grieco M, et al. Developmental expression of the RET protooncogene. Cell Growth Differ. 1994;5(3):305-11.
Schuchardt A, D'Agati V, Larsson-Blomberg L, et al. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature. 1994;367(6461):380-83. doi: https://doi.org/10.1038/367380a0 DOI: https://doi.org/10.1038/367380a0
Mohammadi M, Hedayati M. A brief review on the molecular basis of medullary thyroid carcinoma. Cell J. 2017;18(4):485-92. doi: https://doi.org/10.22074/cellj.2016.4715
Dvorakova S, Vaclavikova E, Duskova J,et al. Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg. J Endocrinol Invest. 2005;28(10):905-9. doi: https://doi.org/10.1007/BF03345322 DOI: https://doi.org/10.1007/BF03345322
Silva AM, Maciel RM, Silva MR, et al. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(11):5438-43. doi: https://doi.org/10.1210/jc.2003-030997 DOI: https://doi.org/10.1210/jc.2003-030997
Raue F, Frank-Raue K. Genotype-phenotype correlation in multiple endocrine neoplasia type 2. Clinics (Sao Paulo). 2012;67(Supl1):69-75. doi: https://doi.org/10.6061/clinics/2012(sup01)13 DOI: https://doi.org/10.6061/clinics/2012(Sup01)13
Wells SA Jr, Pacini F, Robinson BG, et al. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab. 2013;98(8):3149-64. doi: https://doi.org/10.1210/jc.2013-1204 DOI: https://doi.org/10.1210/jc.2013-1204
Chen H, Sippel RS, O'Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775-83. doi: https://doi.org/10.1097/mpa.0b013e3181ebb4f0 DOI: https://doi.org/10.1097/MPA.0b013e3181ebb4f0
Maia AL, Siqueira DR, Kulcsar MA, et al. Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2014;58(7):667-700. doi: https://doi.org/10.1590/0004-2730000003427 DOI: https://doi.org/10.1590/0004-2730000003427
Eng C, Mulligan LM, Smith DP, et al. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer. 1995;12(3):209-12. doi: https://doi.org/10.1002/gcc.2870120308 DOI: https://doi.org/10.1002/gcc.2870120308
Marsh DJ, Learoyd DL, Andrew SD, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf). 1996;44(3):249-57. doi: https://doi.org/10.1046/j.1365-2265.1996.681503.x DOI: https://doi.org/10.1046/j.1365-2265.1996.681503.x
Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol. 2016;12(4):192-202. doi: https://doi.org/10.1038/nrendo.2016.11 DOI: https://doi.org/10.1038/nrendo.2016.11
Puñales MK, Graf H, Gross JL, et al. RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. J Clin Endocrinol Metab. 2003;88(6):2644-9. doi: https://doi.org/10.1210/jc.2002-021422 DOI: https://doi.org/10.1210/jc.2002-021422
BioEdit [Internet]. Versão 7.2.5. [sem local]: Informer Technologies, Inc.; ©2008-2024, [acesso 2024 jul 15]. Disponível em: https://bioedit.software.informer.com/7.2/
Altschul SF, Gish W, Miller W, et al. Basic local alignment search tool. J Mol Biol. 1990;215(3):403-10. doi: https://doi.org/10.1016/s0022-2836(05)80360-2 DOI: https://doi.org/10.1016/S0022-2836(05)80360-2
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24. doi: https://doi.org/10.1038/gim.2015.30 DOI: https://doi.org/10.1038/gim.2015.30
Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42(Database issue):D980-5. doi: https://doi.org/10.1093/nar/gkt1113 DOI: https://doi.org/10.1093/nar/gkt1113
Graph Pad: Prism [Internet]. Versão 7.0.0. Boston: GraphPad; 2017. [acesso 2024 jul 19]. Disponível em: https://www.graphpad.com/updates
Conselho Nacional de Saúde (BR). Resolução n° 466, de 12 de dezembro de 2012. Aprova as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. Diário Oficial da União, Brasília, DF. 2013 jun 13; Seção I:59.
Brandão LG, Cavalheiro BG, Junqueira CR. Prognostic influence of clinical and pathological factors in medullary thyroid carcinoma: a study of 53 cases. Clinics (Sao Paulo). 2009;64(9):849-56. doi: https://doi.org/10.1590/S1807-59322009000900005 DOI: https://doi.org/10.1590/S1807-59322009000900005
Martins-Costa MC, Lindsey SC, Cunha LL, et al. A pioneering RET genetic screening study in the State of Ceará, Brazil, evaluating patients with medullary thyroid cancer and at-risk relatives: experience with 247 individuals. Arch Endocrinol Metab. 2018;62(6):623-35. doi: https://doi.org/10.20945/2359-3997000000088 DOI: https://doi.org/10.20945/2359-3997000000088
Sermoud LM, Brochini MM, Rodrigues HD, et al. 15 years of medullary thyroid carcinoma (MTC) hospital morbidity according to Cancer Hospital-Based Registry in Brazil. Braz J Oncol. 2018;14(47):1-9. doi: https://doi.org/10.26790/BJO20181447A209 DOI: https://doi.org/10.26790/BJO20181447A209
Raue F. German medullary thyroid carcinoma/multiple endocrine neoplasia registry. Langenbecks Arch Surg. 1998;383(5):334-6. doi: https://doi.org/10.1007/s004230050143 DOI: https://doi.org/10.1007/s004230050143
Instituto Nacional de Câncer. Estimativa 2023: Incidência de câncer no brasil [Internet]. Rio de Janeiro: Instituto Nacional de Câncer José Alencar Gomes da Silva; 2022. [acesso 2023 dez 15]. Disponível em: https://www.inca.gov.br/publicacoes/livros/estimativa-2023-incidencia-de-cancer-no-brasil
Randle RW, Balentine CJ, Leverson GE, et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery. 2017;161(1):137-46. doi: https://doi.org/10.1016/j.surg.2016.04.053 DOI: https://doi.org/10.1016/j.surg.2016.04.053
Correia-Deur JE, Toledo RA, Imazawa AT, et al. Sporadic medullary thyroid carcinoma: clinical data from a university hospital. Clinics (Sao Paulo). 2009;64(5):379-86. doi: https://doi.org/10.1590/s1807-59322009000500002 DOI: https://doi.org/10.1590/S1807-59322009000500002
Chow SM, Chan JK, Tiu SC, et al. Medullary thyroid carcinoma in Hong Kong Chinese patients. Hong Kong Med J. 2005;11(4):251-8.
Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134-42. doi: https://doi.org/10.1002/cncr.22244 DOI: https://doi.org/10.1002/cncr.22244
Calvo J, Torrealba G, Sáenz A, et al. Genetic and clinical features of medullary thyroid carcinoma: the experience of a single center in Costa Rica. J Cancer Epidemiol. 2016;2016:9637173. doi: https://doi.org/10.1155/2016/9637173 DOI: https://doi.org/10.1155/2016/9637173
Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist. 2008;13(5):539-47. doi: https://doi.org/10.1634/theoncologist.2007-0239 DOI: https://doi.org/10.1634/theoncologist.2007-0239
Raue F, Kotzerke J, Reinwein D, et al. Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Investig. 1993;71(1):7-12. doi: https://doi.org/10.1007/bf00210956b DOI: https://doi.org/10.1007/BF00210956
Dralle H, Scheumann GF, Proye C, et al. The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study. J Intern Med. 1995;238(4):357-61. doi: https://doi.org/10.1111/j.1365-2796.1995.tb01210.x DOI: https://doi.org/10.1111/j.1365-2796.1995.tb01210.x
Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg. 1999;229(6):880-7. doi: https://doi.org/10.1097/00000658-199906000-00016 DOI: https://doi.org/10.1097/00000658-199906000-00016
Scollo C, Baudin E, Travagli JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2003;88(5):2070-5. doi: https://doi.org/10.1210/jc.2002-021713 DOI: https://doi.org/10.1210/jc.2002-021713
Newey PJ. Multiple endocrine neoplasia. Medicine. 2021;49(9):539-43. doi: https://doi.org/10.1016/j.mpmed.2021.06.003 DOI: https://doi.org/10.1016/j.mpmed.2021.06.003
Romei C, Pardi E, Cetani F, et al. Genetic and clinical features of multiple endocrine neoplasia types 1 and 2. J Oncol. 2012;2012:1-15. doi: https://doi.org/10.1155/2012/705036 DOI: https://doi.org/10.1155/2012/705036
Maciel RMB, Maia AL. Global Endocrinology: geographical variation in the profile of ret variants in patients with medullary thyroid cancer: a comprehensive review. Eur J Endocrinol. 2021;186(1):R15-30. doi: https://doi.org/10.1530/EJE-21-0753 DOI: https://doi.org/10.1530/EJE-21-0753
Maciel RMB, Camacho CP, Assumpção LVM, et al. Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study. Endocr Connect. 2019;8(3):289-98. doi: https://doi.org/10.1530/EC-18-0506 DOI: https://doi.org/10.1530/EC-18-0506
Siqueira DR, Ceolin L, Ferreira CV, et al. Role of RET genetic variants in MEN2-associated pheochromocytoma. Eur J Endocrinol. 2014;170(6):821-8. doi: https://doi.org/10.1530/EJE-14-0084 DOI: https://doi.org/10.1530/EJE-14-0084
Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2003;349(16):1517-25. doi: https://doi.org/10.1056/nejmoa012915 DOI: https://doi.org/10.1056/NEJMoa012915
Frank-Raue K, Höppner W, Frilling A, et al. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. J Clin Endocrinol Metab. 1996;81(5):1780-3. doi: https://doi.org/10.1210/jcem.81.5.8626834 DOI: https://doi.org/10.1210/jc.81.5.1780
Romei C, Mariotti S, Fugazzola L, et al. ItaMEN network. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol. 2010;163(2):301-8. doi: https://doi.org/10.1530/eje-10-0333 DOI: https://doi.org/10.1530/EJE-10-0333
Qi XP, Chen XL, Ma JM, et al. RET proto-oncogene genetic screening of families with multiple endocrine neoplasia type 2 optimizes diagnostic and clinical management in China. Thyroid. 2012;22(12):1257-65. doi: https://doi.org/10.1089/thy.2012.0134 DOI: https://doi.org/10.1089/thy.2012.0134
Ceolin L, Siqueira DR, Ferreira CV, et al. Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness. Eur J Endocrinol. 2012;166(5):847-54. doi: https://doi.org/10.1530/EJE-11-1060 DOI: https://doi.org/10.1530/EJE-11-1060
Magalhães PK, Castro M, Elias LL,. Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma. Thyroid. 2004;14(10):848-52. doi: https://doi.org/10.1089/thy.2004.14.848 DOI: https://doi.org/10.1089/thy.2004.14.848
Wiench M, Wygoda Z, Gubala E, et al. Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J Clin Oncol. 2001;19(5):1374-80. doi: https://doi.org/10.1200/jco.2001.19.5.1374 DOI: https://doi.org/10.1200/JCO.2001.19.5.1374
Sromek M, Czetwertyńska M, Skasko E, etal. The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central. Poland. Endocr Pathol. 2010;21(3):178-85. doi: https://doi.org/10.1007/s12022-010-9125-8 DOI: https://doi.org/10.1007/s12022-010-9125-8
Lebeault M, Pinson S, Guillaud-Bataille M, et al. Nationwide french study of RET variants detected from 2003 to 2013 suggests a possible influence of polymorphisms as modifiers. Thyroid. 2017;27(12):1511-22. doi: https://doi.org/10.1089/thy.2016.0399 DOI: https://doi.org/10.1089/thy.2016.0399
Siqueira DR, Romitti M, Rocha AP, et al. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma. Endocr Relat Cancer. 2010;17(4):953-63. doi: https://doi.org/10.1677/erc-09-0312 DOI: https://doi.org/10.1677/ERC-09-0312
Machens A, Frank-Raue K, Lorenz K, et al. Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer. Clin Endocrinol (Oxf). 2012;76(5):691-7. doi: https://doi.org/10.1111/j.1365-2265.2011.04293.x DOI: https://doi.org/10.1111/j.1365-2265.2011.04293.x
Zhang Y, Wang S, Chen X, et al. Quantitative assessment of the association between L769L and S836S polymorphisms at RET gene and medullary thyroid carcinoma risk. Tumour Biol. 2014;35(7):6641-7. doi: https://doi.org/10.1007/s13277-014-1878-0 DOI: https://doi.org/10.1007/s13277-014-1878-0
Skalniak A, Trofimiuk-Müldner M, Przybylik-Mazurek E, et al. Modifier role of common RET variants in sporadic medullary thyroid carcinoma. Int J Mol Sci. 2021;22(21):11794. doi: https://doi.org/10.3390/ijms222111794 DOI: https://doi.org/10.3390/ijms222111794
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
